Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2011

View Archived Issues

Novartis reflects on accomplishments of second quarter 2011

Byetta is safe and effective in Prader-Willi syndrome

Pfizer presents new MABA as clinical candidate for COPD

Diagnostic ability of PET tracer flutemetamol investigated in AD, MCI and NPH

Sanofi discloses novel protein kinase inhibitors

Takeda presents new histamine H3 receptor antagonists

Novel agents for protozoal infections claimed by Actelion

Piramal Life Sciences claims new diacylglycerol O-acyltransferase inhibitors

Katholieke Universiteit Leuven prepares novel antibacterials

Trial measures lorcaserin exposure in human cerebrospinal fluid

Femta Pharmaceuticals files IND with FDA for FM-101

Cardium Therapeutics provides update on plan to acquire Transdel

Noninvasive diabetes screening test obtains CE mark

Critical Outcome Technologies begins synthesis of AML drug candidates

FDA accepts NDA filing for Levadex

Genzyme seeks approval for mipomersen in Europe

Protalix replies to FDA complete response letter for taliglucerase alfa

AAV-mediated gene editing using ZFN technology shows promise to treat hemophilia in vivo

Alnylam completes phase I ALN-VSP trial

OncoTherapy Science's anticancer vaccine OTS-102 obtains generic name

Amarin completes remaining studies of AMR-101 required for NDA

Bionomics provides update on clinical trials of anticancer candidate BNC-105

Encouraging interim results emerge from phase III study of Paclical

EMA provides scientific advice regarding phase III trial of CPP-1X in FAP

European Commission expands RoActemra label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...